Senior Executives with Insulet Corporation recently announced their milestone of achieving 100,000 active users worldwide of the Omnipod® Insulin Management System. The Omnipod® System received FDA clear- ance in 2005 as the first tubeless insulin delivery system that provides users known as PoddersTM with a tube- less, waterproof* patch-pump technology designed to improve quality of life for people with diabetes.

Insulet celebrated this significant milestone during National Diabetes Awareness Month this past November by conducting several events aimed at spreading awareness around diabetes and the Omnipod® System.

The Omnipod® System offers the convenience of continuous subcutaneous insulin infusion therapy (CSII), with the ability to provide up to 72 continuous hours of discreet insulin delivery. The system features include a Pod that stores and delivers insulin, as well as a Personal Diabetes Manager or PDM that wirelessly programs and controls the user’s personalized insulin delivery, calculates suggested doses and insulin on board, and contains a built-in blood glucose meter. The Omnipod® System conveniently eliminates the need for multiple daily injections.

Data published in Diabetes Technology & Therapeutics reinforced the clinical benefits of the Omnipod® System for individuals’ diabetes man- agement. The study demonstrated that PoddersTM reported improvements in perceived control over their diabetes (72.5%), diabetes distress (69.6%), overall well-being (53.5%), and hypoglycemic safety (50.6%). The majority of users also reported significant improvements in control of their dia- betes.

“We have always had a strong commitment to our PodderTM community,” Patrick Sullivan, Chairman and Chief Executive Officer, said in a press release. “We are proud to bring our differentiated technology to people across the world to give people with diabetes a sense of freedom and control.”

*Waterproof Pod: IPX8 (25 feet for up to 60 minutes). The PDM is not waterproof.


Polonsky WH, Hessler D, Layne JE, Zisser H. Impact of the Omnipod® Insulin Management System on Quality of Life: A Survey of Current Users. Diabetes Technology & Therapeutics. 2016; 18(10): 664-670.